OLMA_OUT_1 [2025-04-04 06:01:17 -0400] 2992 Bytes | 786 tokens | Cum: 786 tkns (9.83% of 8k)
==========================================================================

We need a winner today and it's already 6:01:16 AM on Fri Apr 04, 2025 -0400 ... So let's find out if Olema Pharmaceuticals (OLMA) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 3.9 up from 3.35. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Olema Pharmaceuticals (OLMA)
IPO: 2020-11-19 (4 Years Ago)
Market Cap: $228,915,768
Shares Outstanding: 68,330,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

Here’s the first list of news for Olema Pharmaceuticals:

C1 - Apr-02-25 04:30PM - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C2 - Mar-25-25 04:31PM - Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting
C3 - Mar-18-25 04:01PM - Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
C4 - Mar-04-25 04:30PM - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C5 - Feb-19-25 04:30PM - Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
C6 - Feb-18-25 07:00AM - Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary
C7 - Feb-04-25 04:30PM - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C8 - Feb-03-25 04:30PM - Olema Oncology to Participate in Upcoming Investor Conferences

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Olema Pharmaceuticals (OLMA).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

OLMA_OUT_3 [2025-04-04 06:01:22 -0400] 1109 Bytes | 323 tokens | Cum: 1111 tkns (13.89% of 8k)
==========================================================================

Showing C3 (chunk 1 of 14): C3:
**Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results**
Date: Mar-18-25 04:01PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/18/3044958/0/en/Olema-Oncology-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-and-Operating-Results.html

March 18, 2025 16:01 ET| Source:Olema OncologyOlema Oncology

SAN FRANCISCO, March 18, 2025 (GLOBE NEWSWIRE) --Olema Pharmaceuticals, Inc.(“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2024.

“2024 was a productive year for Olema and we closed the year with significant positive momentum. We announced a new clinical trial collab

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OLMA_OUT_5 [2025-04-04 06:01:23 -0400] 993 Bytes | 298 tokens | Cum: 1498 tkns (18.73% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T09:20:41Z - Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarke...
A2 - 2025-04-04T07:55:39Z - Pictet Asset Management Holding SA Boosts Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA...
A3 - 2025-04-02T20:53:54Z - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Taiwan News | Apr. 3...
A4 - 2025-04-02T20:40:18Z - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
A5 - 2025-04-02T20:41:05Z - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

OLMA_OUT_7 [2025-04-04 06:01:27 -0400] 1098 Bytes | 308 tokens | Cum: 1808 tkns (22.60% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Compass Minerals Intl (NYSE:CMP), Adaptive Biotechnologies (NASDAQ:ADPT)**Date: 2025-04-04Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/25/04/44642662/why-sangamo-therapeutics-shares-are-trading-higher-by-around-40-here-are-20-stocks-moving-premarketShares of Sangamo Therapeutics, Inc. SGMO rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co LLY, granting the company a worldwide exclusive license to leverage the company's novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.

Sangamo Therapeutics shares jumped 39.5% to $0.8684 in pre-market trading

Here are some other stocks moving in pre-market trading.

Gainers Impact BioM

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OLMA_OUT_9 [2025-04-04 06:01:28 -0400] 988 Bytes | 306 tokens | Cum: 2194 tkns (27.43% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-03T21:30:00Z - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B2 - 2025-01-02T12:00:00Z - Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
B3 - 2024-12-10T12:00:00Z - Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
B4 - 2024-09-04T20:49:00Z - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
B5 - 2024-08-21T11:00:00Z - Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
B6 - 2024-07-02T20:31:49Z - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OLMA_OUT_11 [2025-04-04 06:01:31 -0400] 758 Bytes | 224 tokens | Cum: 2420 tkns (30.25% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/03/3004177/0/en/Olema-Oncology-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.htmlOlema Pharmaceuticals, a clinical-stage biopharmaceutical company, announced that it has granted stock options to three new employees to purchase a total of 26,200 shares of the company's common stock. The stock options have a 10-year term and an exercise price of $5.57 per share.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OLMA_OUT_13 [2025-04-04 06:01:31 -0400] 1102 Bytes | 286 tokens | Cum: 2770 tkns (34.62% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond.

On March 18, 2025, Olema Pharmaceuticals, Inc. (the Company) reported its financial results for the year ended December 31, 2024. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and i...

S2 - 2025-03-18 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following managements discussion and analysis of our financial condition and results of operations should be read in conjunction with the CONS financial statements and not...

S3 - 2025-03-05 8-K Item 7.01 Regulation FD Disclosure.

On March 5, 2025, Olema Pharmaceuticals, Inc. (the Company) made available on its website a copy of the Companys presentation to be shared with investors and others from time to time. The presentation is being furnished as Exhibit 99.1 to thi...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

OLMA_OUT_15 [2025-04-04 06:01:41 -0400] 1080 Bytes | 276 tokens | Cum: 3048 tkns (38.10% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 18, 2025, Olema Pharmaceuticals, Inc. (the Company) reported its financial results for the year ended December 31, 2024. A copy of the press release is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

OLMA_OUT_17 [2025-04-04 06:01:52 -0400] 9951 Bytes | 2712 tokens | Cum: 5884 tkns (73.55% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+----------------------+
| Volume: 1,400,263 | Perf Month: -21.36% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 1.07M | Perf Quarter: -42.54% | Short Float: 15.90% | ROE: -39.07% |
+--------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 1.31 | Index: RUT | Short Ratio: 8.12 | ROI: -31.64% |
+--------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 25.61 | Market Cap: 228.92M | Short Interest: 8.69M | Sales Surprise: - |
+--------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.35 | Shs Outstand: 74.31M | Beta: 2.11 | EPS Surprise: 19.80% |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA20: -18.73% | Shs Float: 54.63M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA50: -30.55% | Inst Own: 84.41% | Sales past 5Y: 0.00% | Earnings: Mar 18 AMC |
+--------------------+-----------------------+-------------------------+----------------------+
| SMA200: -64.22% | Insider Own: 20.05% | Employees: 96 | |
+--------------------+-----------------------+-------------------------+----------------------+
| Perf Week: -20.24% | Insider Trans: -4.30% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: Olema Pharmaceuticals, Inc. (OLMA) by Myles David C. (CH. DISCOV. & NON-CLIN DEV OFF) on 2025-02-28
- Stock Option (Right to Buy): 205000 shares at $0 (D)

Inside Trans: Olema Pharmaceuticals, Inc. (OLMA) by Zojwalla Naseem (CHIEF MEDICAL OFFICER) on 2025-02-28
- Stock Option (Right to Buy): 205000 shares at $0 (D)

Inside Trans: Olema Pharmaceuticals, Inc. (OLMA) by Mitchell Shawnte (CHIEF LEGAL OFFICER) on 2025-02-28
- Stock Option (Right to Buy): 450000 shares at $0 (D)

Inside Trans: Olema Pharmaceuticals, Inc. (OLMA) by Kovacs Shane William Charles (CH. OPERATING & FINANCIAL OFF.) on 2025-02-28
- Stock Option (Right to Buy): 320000 shares at $0 (D)

Inside Trans: Olema Pharmaceuticals, Inc. (OLMA) by Bohen Sean (PRESIDENT AND CEO) on 2025-02-28
- Stock Option (Right to Buy): 650000 shares at $0 (D)

No transactions recorded.

Inside Trans: Olema Pharmaceuticals, Inc. (OLMA) by BVF PARTNERS L P/IL (Unknown Title) on 2025-01-10
- Common stock, $0.0001 par value: 235450 shares at $N/A (D) Footnote: Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3.
- Common stock, $0.0001 par value: 161810 shares at $N/A (D) Footnote: Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3.
- Common stock, $0.0001 par value: 22740 shares at $N/A (D) Footnote: Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3.
- Pre-Funded Warrant: 235450 shares at $N/A (D) Footnote: Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3.
- Pre-Funded Warrant: 161810 shares at $N/A (D) Footnote: Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3.
- Pre-Funded Warrant: 22740 shares at $N/A (D) Footnote: Certain of the Reporting Persons entered into an Exchange Agreement with the Issuer, dated January 10, 2025 (the "Exchange Agreement"), pursuant to which such Reporting Persons agreed to exchange an aggregate of 420,000 shares of Common Stock of the Issuer for a total of 420,000 Pre-Funded Warrants (the "Pre-Funded Warrants"). Pursuant to the Exchange Agreement, BVF exchanged 235,450 shares for 235,450 Pre-Funded Warrants, BVF2 exchanged 161,810 shares for 161,810 Pre-Funded Warrants and Trading Fund OS exchanged 22,740 shares for 22,740 Pre-Funded Warrants. These transactions are exempt from Section 16 pursuant to Rule 16b-3.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -129474000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.35
Average Volume: 1020136.18
30-Day High: 4.61
30-Day Low: 3.33

[Detailed Financials: TTM 2024]
- Total Assets: $450,979,000.0
- Total Liabilities: $42,015,000.0
- Total Equity: $408,964,000.0
- Current Assets: $438,473,000.0
- Current Liabilities: $41,758,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.2

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $70,941,000.0

[Detailed Financials: FY 2024]
- Total Assets: $450,979,000.0
- Total Liabilities: $42,015,000.0
- Total Equity: $408,964,000.0
- Current Assets: $438,473,000.0
- Current Liabilities: $41,758,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.2

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $70,941,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

OLMA_OUT_19 [2025-04-04 06:01:54 -0400] 687 Bytes | 169 tokens | Cum: 6304 tkns (78.80% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

OLMA_IN_21 [2025-04-04 06:01:55 -0400] 126 Bytes | 29 tokens | Cum: 6363 tkns (79.54% of 8k)
==========================================================================

====================================
[2025-04-04 06:01:55] # Analysis Completed
Elapsed Time: 38.74 seconds